New Jersey S4073 requires health insurance and Medicaid coverage for diagnostic testing and treatments to slow Alzheimer's disease progression.
New Jersey S4073 mandates that health insurance and Medicaid cover diagnostic testing and U.S. Food and Drug Administration-approved treatments or medications prescribed to slow the progression of Alzheimer's disease and related disorders. This applies to various types of health insurance policies and contracts, including those issued by health maintenance organizations, health service corporations, and medical service corporations. The coverage must be provided to the same extent as for any other condition, with no step therapy requirements for these treatments.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.